

The architecture of the OmpC–MlaA complex sheds light on the maintenance of outer membrane lipid asymmetry in *Escherichia coli*

Received for publication, February 15, 2018, and in revised form, May 2, 2018. Published, Papers in Press, May 30, 2018, DOI 10.1074/jbc.RA118.002441

Jiang Yeow^{†S1}, Kang Wei Tan^{†1}, Daniel A. Holdbrook^{¶1}, Zhi-Soon Chong[‡], Jan K. Marzinek^{¶||}, Peter J. Bond^{¶||2}, and Shu-Sin Chng^{†***3}

From the [†]Department of Chemistry, National University of Singapore, Singapore 117543, the [§]National University of Singapore Graduate School for Integrative Sciences and Engineering, Singapore 117456, the [¶]Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore 138671, the ^{||}Department of Biological Sciences, National University of Singapore, Singapore 117543, and the ^{**}Singapore Center for Environmental Life Sciences Engineering, National University of Singapore, Singapore 117456

Edited by Karen G. Fleming

A distinctive feature of the Gram-negative bacterial cell envelope is the asymmetric outer membrane (OM), where lipopolysaccharides and phospholipids (PLs) reside in the outer and inner leaflets, respectively. This unique lipid asymmetry renders the OM impermeable to external insults, including antibiotics and bile salts. In *Escherichia coli*, the complex comprising osmoporin OmpC and the OM lipoprotein MlaA is believed to maintain lipid asymmetry by removing mislocalized PLs from the outer leaflet of the OM. How this complex performs this function is unknown. Here, we defined the molecular architecture of the OmpC–MlaA complex to gain insights into its role in PL transport. Using *in vivo* photo-cross-linking and molecular dynamics simulations, we established that MlaA interacts extensively with OmpC and is located entirely within the lipid bilayer. In addition, MlaA forms a hydrophilic channel, likely enabling PL translocation across the OM. We further showed that flexibility in a hairpin loop adjacent to the channel is critical in modulating MlaA activity. Finally, we demonstrated that OmpC plays a functional role in maintaining OM lipid asymmetry together with MlaA. Our work offers glimpses into how the OmpC–MlaA complex transports PLs across the OM and has important implications for future antibacterial drug development.

The outer membrane (OM)⁴ of Gram-negative bacteria is an extremely asymmetric bilayer, comprising lipopolysaccharides (LPS) in the outer leaflet and phospholipids (PLs) in the inner leaflet (1, 2). LPS molecules pack tightly together in the presence of divalent cations to form an outer layer with markedly reduced fluidity and permeability (3). Thus, the OM serves as an effective barrier against toxic compounds including detergents and antibiotics. This function is fully dependent on the establishment and maintenance of lipid asymmetry; cells generally become more sensitive to external insults when OM lipid asymmetry is disrupted, which is typically characterized by the accumulation of PLs in the outer leaflet (4, 5). The OM is also essential for viability.

The requisite lipid asymmetry of the OM is likely initially established by direct placement of LPS and PLs into the outer and inner leaflets, respectively. LPS assembly into the outer leaflet of the OM is mediated by the well-established Lpt (lipopolysaccharide transport) machinery (6), but proteins that transport and insert PLs into the inner leaflet have not been identified. For entropic reasons, there is a natural tendency for PLs to appear in the outer leaflet of the OM, although how they traverse the bilayer is unclear. This occurs more readily with perturbations in the OM, especially when assembly of other OM components is disrupted (4, 5, 7). Because loss of lipid asymmetry compromises the barrier function of the OM, several mechanisms exist to remove PLs aberrantly localized in the outer leaflet of the membrane: (i) the OM phospholipase OmpLA hydrolyzes both acyl chains from outer leaflet PLs (8), (ii) the OM acyltransferase PagP transfers an acyl chain from outer leaflet PLs to LPS (9) or phosphatidylglycerol (10), and (iii) the OmpC–Mla system, a putative PL trafficking pathway,

This work was supported by funds from the National University of Singapore Graduate School for Integrative Sciences and Engineering scholarship (to J. Y.). Computational work was supported in part by the Singapore Ministry of Education Academic Research Fund Tier 3 Grant MOE2012-T3-1-008 (to J. K. M. and P. J. B.). All experimental work was supported by the National University of Singapore start-up funding and the Singapore Ministry of Education Academic Research Fund Tier 1 Grant and Tier 2 Grant MOE2013-T2-1-148 (to S.-S. C.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains references, Tables S1–S4, and Figs. S1–S14.

¹ These authors contributed equally to this work.

² To whom correspondence may be addressed: Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore 138671. E-mail: peterjb@bii.a-star.edu.sg.

³ To whom correspondence may be addressed: Dept. of Chemistry, National University of Singapore, Singapore 117543. E-mail: chmchngs@nus.edu.sg.

⁴ The abbreviations used are: OM, outer membrane; LPS, lipopolysaccharide; PL, phospholipid; Lpt, lipopolysaccharide transport; IM, inner membrane; MD, molecular dynamics; pBpa, *para*-benzoyl-L-phenylalanine; SEC, size-exclusion chromatography; MALS, multiangle light scattering; RMSD, root-mean-square deviation; SCAM, substituted cysteine accessibility method; MTSES, sodium (2-sulfonatoethyl)-methanethiosulfonate; PMSF, phenylmethylsulfonyl fluoride; DDM, *n*-dodecyl β -D-maltoside; TBS, Tris-buffered saline; NEM, *N*-ethylmaleimide; Mal-PEG, maleimide-PEG; HRP, horseradish peroxidase.

MlaA forms an outer membrane channel

removes outer leaflet PLs and shuttles them back to the inner membrane (IM) (11, 12).

The OmpC–Mla system comprises seven proteins located across the cell envelope. Removing any component results in PL accumulation in the outer leaflet of the OM and therefore sensitivity to SDS/EDTA (11, 12). The OM lipoprotein MlaA forms a complex with osmoporin OmpC that likely extracts PLs from the outer leaflet of the OM (12). The periplasmic protein MlaC serves as a lipid chaperone and is proposed to transport lipids from the OmpC–MlaA complex to the IM (11, 13, 14). At the IM, MlaF and MlaE constitute an ATP-binding cassette family transporter together with two auxiliary proteins, MlaD and MlaB (14, 15); this complex presumably receives PLs from MlaC and inserts them into the membrane. MlaD has been shown to bind PLs, whereas MlaB is important for both assembly and activity of the transporter (15). Recently, the function of the OmpC–Mla system in retrograde (OM-to-IM) PL transport has been demonstrated in *Escherichia coli* (7).

The molecular mechanism by which the OmpC–MlaA complex extracts PLs from the outer leaflet of the OM, presumably in an energy-independent manner, is an interesting problem. Aside from the LptDE machine, which assembles LPS on the surface (4, 5), the OmpC–MlaA complex is the only other system proposed to catalyze the translocation of lipids across the OM. OmpC is a classical trimeric porin that typically only allows passage of hydrophilic solutes across the OM (3, 16), although MlaA is believed to be anchored to the inner leaflet of the membrane; how the two proteins are organized in a complex for the translocation of amphipathic PLs is not known. In this paper, we establish that MlaA is in fact an integral membrane protein that forms a channel adjacent to OmpC trimers in the OM, likely allowing the passage of PLs. We first demonstrated that MlaA binds the OmpC trimer within the OM bilayer by mapping the interaction surfaces using *in vivo* cross-linking. Using a recently predicted structural model of MlaA (17), we obtained molecular views of the OmpC–MlaA complex by molecular dynamics (MD) simulations, and experimentally established the existence of a hydrophilic channel within OM-embedded MlaA. Combining charge mutations in this channel modulated MlaA activity, suggesting functional importance. Furthermore, mutations altering the flexibility of a hairpin loop that could interact with the hydrophilic channel led to predictable *in vivo* effects on MlaA function. Finally, we identified a key residue on OmpC found at the OmpC–MlaA interacting surface that is important for proper function of the complex. Our findings provide important mechanistic insights into how PLs may be translocated across the OM to ensure proper lipid asymmetry.

Results

The OmpC trimer contacts MlaA directly along its membrane-facing dimeric interfaces

To develop a detailed architectural understanding of the OmpC–MlaA complex, we carried out *in vivo* photo-cross-linking to map intermolecular interactions within the complex. Guided by the crystal structure of the OmpC trimer (18), we introduced the UV-cross-linking amino acid, *para*-benzoyl-L-

phenylalanine (*p*Bpa), at 49 positions in OmpC via amber suppression (19). Initial selection focused on residues that are either solvent-accessible (*i.e.* loop and lumen) or located near the membrane–water boundaries (*i.e.* aromatic girdle). Upon UV irradiation, a ~65-kDa cross-linked band that contains both OmpC (~37 kDa) and MlaA (~28 kDa) could be detected in cells expressing OmpC variants substituted with *p*Bpa at three positions (Leu⁵⁰, Gln⁸³, or Phe²⁶⁷) (Fig. 1A). These residues are found on the periplasmic turns at the dimeric interfaces of the OmpC trimer (Fig. 1C), thus localizing possible binding sites for MlaA. We have previously proposed that OmpC may allow MlaA to traverse the bilayer and gain access to PLs that have accumulated in the outer leaflet of the OM (12). Because none of the six selected residues in the OmpC lumen cross-linked to MlaA, we decided to probe for interactions between MlaA and the membrane-facing side walls of OmpC, specifically around the dimeric interfaces of the OmpC trimer. Remarkably, of the additional 49 positions tested in this region, 10 residues allowed photoactivated cross-links between OmpC and MlaA when replaced with *p*Bpa (Fig. 1B and Fig. S1). In total, these 13 cross-linking residues clearly demarcate an extensive MlaA-interacting surface on OmpC (Fig. 1C). This explains why OmpC exhibits strong interactions and can be co-purified with MlaA on an affinity column, as we have previously reported (12). Two positions, Tyr¹⁴⁹ and Leu³⁴⁰, are located right at or near the membrane–water boundary exposed to the extracellular environment, suggesting that MlaA traverses the entire width of the OM. We conclude that MlaA binds along the dimeric interfaces of the OmpC trimer in the membrane.

MlaA resides entirely in the OM bilayer and contacts the OmpC trimer via two specific regions

We sought to map in greater detail the OmpC–MlaA interacting surface *in vitro*. To do that, we first overexpressed and purified the OmpC–MlaA complex to homogeneity. We showed that this complex forms a single peak on size-exclusion chromatography (SEC) (Fig. 2A). OmpC within this complex exhibits the characteristic heat-modifiable gel shift commonly observed for OM β -barrel proteins (20), consistent with the presence of the folded trimer. Multiangle light scattering (MALS) analysis revealed that one copy of MlaA interacts with the OmpC trimer (Fig. S2), suggesting that only one of the three dimeric interfaces within the trimer is available for binding (Fig. 1C). We next performed protease digestion experiments to identify specific region(s) on MlaA that may interact stably with OmpC. OM β -barrel proteins such as OmpC are known to be protease-resistant (21). Given that some parts of MlaA contact OmpC within the membrane, we expect these bound regions to also be protected from proteolytic degradation. Treatment of the purified OmpC–MlaA complex with trypsin results in almost complete degradation of MlaA, with the OmpC trimer remaining intact (Fig. 2A). Following SEC, however, we found that an ~8-kDa peptide (presumably from MlaA) remains stably bound to the trimer. N-terminal sequencing and tandem MS analyses revealed that this peptide corresponds to MlaA_{D61–K124} (Fig. 2, A and C, and Fig. S3). These results sug-




Figure 1. MlaA binds at the dimeric interfaces of the OmpC trimer *in vivo*. *A* and *B*, representative immunoblots showing UV-dependent formation of cross-links between OmpC and MlaA in $\Delta ompC$ cells expressing OmpC substituted with $pBpa$ at the indicated positions, selected in a global (*A*) or localized (*B*) search. *C*, side (*left panel*) and top (*right panel*) views of cartoon representations of the crystal structure of *E. coli* OmpC (Protein Data Bank code 2J1N) (18) with positions that cross-link to MlaA highlighted. Residues selected in the global search for MlaA interaction are colored cyan (no cross-links) and blue (sticks; cross-links detected), whereas those selected in the localized search are colored light pink (no cross-links) and red (sticks; cross-links detected). The OM boundary is indicated as gray dashed lines. MlaA binding sites are indicated as solid or dashed curves on the top-view representation. The figures were generated using the program Chimera (54).

gest that MlaA interacts strongly with OmpC in the membrane in part via this specific region.

To define how OmpC contacts the MlaA_{D61–K124} peptide, we next attempted to overexpress and purify $pBpa$ -containing OmpC variants in complex with MlaA and determine which of the previously identified 13 OmpC residues interacts with MlaA_{D61–K124} *in vitro*. We sequentially performed UV cross-linking and trypsin digestion to potentially link MlaA_{D61–K124} to specific residues on OmpC. This approach may also allow trapping of other potential interacting regions of MlaA, which might not have been stably retained on the WT complex after trypsin digestion. We successfully detected trypsin-resistant cross-linked products for seven OmpC _{$pBpa$} –MlaA complexes (Fig. 2B); they appeared slightly above OmpC between 37 and 50 kDa, indicating that peptides in the range of ~6–10 kDa are cross-linked to OmpC. N-terminal sequencing of six of the seven adducts showed the presence of

OmpC and an MlaA peptide beginning at residue Asp⁶¹ (Fig. 2, C and D, and Fig. S3C). Given the approximate sizes of the cross-linked adducts, we concluded that all these residues interact with MlaA_{D61–K124}. Interestingly, an additional peptide on MlaA starting at residue Phe¹³³ was also found to cross-link at two (Tyr¹⁴⁹ and Leu³⁴⁰) of these six positions on OmpC (Fig. 2, B–D, and Fig. S3C). These adducts can be detected by an α -MlaA antibody that recognizes an epitope within Val¹⁸²–Gln¹⁹⁵ on MlaA (Fig. 2B), suggesting that a peptide from Phe¹³³ to at least Arg²⁰⁵ (next trypsin cleavage site) may be cross-linked (Fig. 2C). Thus, in addition to MlaA_{D61–K124}, our cross-linking strategy revealed a second point of contact (MlaA_{F133–R205}) between OmpC and MlaA.

At the point of these findings, there was no available molecular structure for MlaA; however, a structural model has been predicted based on residue–residue contacts inferred from co-evolution analysis of metagenomic sequence data (17). Using a

MlaA forms an outer membrane channel




Figure 2. OmpC contacts two specific regions on MlaA. *A*, SEC profiles and SDS-PAGE analyses of purified OmpC-MlaA-His complex before (*black*) or after (*red*) treatment with trypsin. Peak fractions from SEC were subjected to denaturing SDS-PAGE (15% Tris-HCl gel), followed by Coomassie Blue (CB) staining (*right panel*). Non-trypsin-treated samples were also analyzed by semipreparative SDS-PAGE (*left panel*). Edman degradation and tandem MS analyses revealed that the MlaA peptide that remains bound to OmpC following trypsin treatment begins at Asp⁶¹ (Fig. S3). *B*, SDS-PAGE (15% Tris-HCl gel) and immunoblot analyses of purified OmpC_{pBpa}-MlaA-His complexes following sequential UV irradiation and trypsin digestion. The resulting OmpC_{pBpa}-MlaA_{peptide} cross-linked products were N-terminally sequenced (see Fig. S3). *C*, amino acid sequence of MlaA with the two peptides found cross-linked to OmpC_{pBpa} highlighted (*red*: MlaA_{D61-K124}; *blue*: MlaA_{F133-R205}). The signal sequence and α -MlaA binding epitope are *underlined* and annotated. *D*, cartoon representations of the crystal structure of *E. coli* OmpC with positions that cross-link to specific MlaA peptides indicated (*left*) and a structural model of MlaA (17) with peptides cross-linked by OmpC_{pBpa} highlighted (*right*). The OM boundary is indicated as *gray dashed lines*. The figures were generated using the program Chimera (54).

rigorously validated quality score, this method of structure determination has generated reliable models for 614 protein families with currently unknown structures. We experimentally validated the model for MlaA by replacing residue pairs far apart on the primary sequence with cysteines and showed that only those that are highly co-evolved (and predicted to be residue-residue contacts) allow disulfide-bond formation in cells (Fig. S4). We therefore proceeded to use this MlaA model to understand the organization of the OmpC-MlaA complex. Interestingly, the positions of the two OmpC-contacting peptides on the MlaA model are spatially separated in a way consistent with the arrangement of the residues on OmpC that cross-link to each peptide (Fig. 2D). This not only reveals how MlaA may potentially be oriented and organized around the dimeric interface of the OmpC trimer but

also suggests that the entire MlaA molecule may reside in the membrane. In fact, the overall surface of MlaA, other than the putative periplasmic-facing region, is largely hydrophobic (Fig. S5). Furthermore, using all-atomistic MD simulations, we found that the structural fold of MlaA appears to be more stable in a lipid bilayer than in an aqueous environment (Fig. S6). Consistent with this, we noted that even without its N-terminal lipid anchor, MlaA is largely not extracted from total membranes by short washes of high pH, chaotropic, or mild detergent solutions (Fig. S7); its membrane extraction profile is similar to β -barrel proteins but different from known peripheral membrane proteins, indicating that MlaA is stably inserted in the OM as an integral membrane protein. Collectively, these observations lend strong support to the validity of the predicted MlaA structure.

MlaA forms a channel in the OM adjacent to OmpC

To obtain a physical picture of how OmpC interacts with MlaA within the complex, we used MD simulations to dock MlaA onto the OmpC trimer within a PL bilayer. Using a previously reported protocol (22), we first docked the MlaA model onto the OmpC trimer structure, both as rigid bodies. Interestingly, all initial docked structures contained MlaA binding at one dimeric interface of OmpC. Based on information derived from cross-linking, we selected two most consistent models differing slightly in how MlaA is oriented with respect to OmpC for unrestrained refinements using all-atomistic simulations. Multiple simulations were run for each MlaA orientation in a PL bilayer until overall root-mean-square deviations (RMSDs) stabilized; remarkably, the resulting equilibrium models fulfilled all observed experimental cross-linking data. We performed clustering on all available trajectories and identified the most populated conformations of the OmpC–MlaA complex in our simulations (Fig. 3A and Fig. S8A for one MlaA orientation and Fig. 3B and Fig. S8B for the other). These conformational models all show MlaA sitting in the bilayer, tucked nicely into the dimeric interface of the OmpC trimer. Evidently, the MlaA_{D61–K124} peptide interacts extensively with OmpC in these models, consistent with why this peptide remains stably bound to OmpC after protease digestion (Fig. 2A). We also mutated several MlaA residues found at the OmpC–MlaA interfaces to *p*Bpa and performed *in vivo* cross-linking experiments. We identified one position, Leu¹⁰⁹, that allowed strong photoactivatable cross-linking to OmpC when replaced with *p*Bpa (Fig. 3C). This residue lies within the MlaA_{D61–K124} peptide (Fig. 3, A and B), confirming that this region does in fact contact OmpC in cells.

One striking feature present in all the simulated OmpC–MlaA models is a negatively charged hydrophilic channel within MlaA that spans the lipid bilayer (Fig. 4A and Fig. S9). To test the existence of this hydrophilic channel in MlaA, especially in the context of the native OM, we selected 27 residues in and around the putative channel in a representative model (Fig. 4 and Fig. S10) and determined their solvent accessibility in cells using the substituted cysteine accessibility method (SCAM). We first showed that these cysteine mutants are functional (Fig. S10C). Solvent-exposed residues are expected to be reactive with the charged membrane-impermeable thiol-labeling reagent sodium (2-sulfonatoethyl)-methanethiosulfonate (MTSES). Remarkably, we found that residues predicted to be within the putative channel (Fig. 4, A and B) or at the membrane–water boundaries (Fig. S10, A and B) are indeed accessible to MTSES. We therefore conclude that MlaA forms a hydrophilic channel in the OM in cells.

Very recently, crystal structures of MlaA in complex with trimeric porins have in fact been solved (23). Interestingly, the experimentally determined structures of MlaA closely resembled the initial MlaA model predicted from co-evolution analysis (Fig. S11A). These structures revealed that MlaA interacts with trimeric porins in the membrane at one or more of their dimeric interfaces (Fig. S11B), in an orientation similar to one of our simulated OmpC–MlaA models (Fig. 3B). They also showed that MlaA contains a hydrophilic channel. Although




Figure 3. Molecular models of the OmpC–MlaA complex depict how MlaA may interact with OmpC in the OM bilayer. A and B, representative MlaA structures bound to OmpC in two possible orientations selected from all-atomistic MD simulation trajectories. MlaA_{D61–K124} and MlaA_{F133–R205} peptides are highlighted in red and blue, respectively, as in Fig. 2D. Leu¹⁰⁹ is labeled and depicted as black spheres on MlaA. The OM boundaries are indicated as gray dashed lines. The figures were generated using the program VMD (55). C, immunoblots showing UV-dependent formation of a cross-link between MlaA and OmpC in $\Delta mlaA$ cells expressing MlaA_{L109pBpa}-His. As expected, the cross-linked product also exhibits heat-modifiable gel shift, indicative of the presence of OmpC.

these structural and our biochemical/modeling studies are in good agreement, there are some discrepancies between the solved structures and our biochemical data. Specifically, the distances separating porin residues equivalent to Tyr¹⁴⁹/Leu³⁴⁰ in OmpC and the MlaA_{F133–R205} peptide in the solved structures (Fig. S11B) are not consistent with the detection of strong *in vivo* photoactivatable cross-links between these regions in the complex (Fig. 2B). In addition, the proposed locations of some MlaA residues, specifically Met³⁹, Phe⁴², and Asn⁴³, at the interior of the lipid bilayer (Fig. S11B) are not in agreement with high or partial solvent accessibility of these sites in cells, as highlighted in the SCAM data (Fig. S10B). These observations suggest that MlaA might adopt a different conformation in its native environment in the OM than that in a crystal lattice.

MlaA forms an outer membrane channel




Figure 4. MlaA forms a hydrophilic channel in the OM. A, a representative structure of MlaA from all-atomistic MD simulations with its putative channel depicted in gray. Residues in the channel that are fully or partially solvent-accessible, based on SCAM in B, are highlighted in blue and cyan, respectively. The figures were generated using the program VMD (55). B, immunoblots showing Mal-PEG alkylation of MlaA variants containing channel-facing residues substituted with cysteine (as depicted in A) following labeling by membrane-permeable (NEM) or impermeable (MTSES) reagents. Mal-PEG alkylated MlaA_{Cys}-His variants show a ~5-kDa mass shift. Positions fully or partially blocked by MTSES, which reflects the level of solvent accessibility, are highlighted in blue or cyan, respectively.

The MlaA channel is functionally important for OM lipid asymmetry

Based on its function in removing PLs from the outer leaflet of the OM, we hypothesize that this channel may allow passage of charged head groups as PLs translocate across the membrane. To ascertain whether this channel is functionally important, we separately mutated 19 polar and (negatively) charged residues near or within the channel to alanine or arginine and tested for MlaA function. However, all of these MlaA mutants are functional (Fig. 5B and Fig. S12A), indicating that single residue changes are not sufficient to perturb channel properties to affect PL transport. We noticed that four (Asp¹⁶⁰, Asp¹⁶¹, Asp¹⁶⁴, and Asp¹⁶⁷) of the five negatively charged channel residues are in close proximity (Fig. 5A). To alter channel properties more drastically, we combined arginine mutations for these aspartates; interestingly, only the D161R/D167R double mutant (Fig. S12B) and the D160R/D161R/D164R triple mutant (MlaA_{3D3R}) disrupted function; cells expressing these variants are highly sensitive to SDS/EDTA (Fig. 5B and Fig. S12B). For the MlaA_{3D3R} mutant, this is likely due to the accumulation of PLs in the outer leaflet of the OM (as judged by PagP-mediated acylation of LPS; Fig. 5C). In fact, this mutant exhibits OM defects that are more pronounced than the Δ mLaA

strain (Fig. 5B). Furthermore, the 3D3R mutation gives rise to the same defects in strains also expressing the WT mLaA allele, revealing a dominant-negative phenotype (Fig. 5, B and C). We showed that MlaA_{3D3R} is produced at levels comparable with WT MlaA on a plasmid (Fig. S13A) and is still able to interact strongly with OmpC (Fig. S13B). Taken together, these results suggest that the MlaA channel plays a functional role in the maintenance of lipid asymmetry.

Flexibility of a hairpin loop adjacent to the channel in MlaA is required for function

The dominant-negative phenotype of the mLaA_{3D3R} mutant is similar to a previously reported mLaA* (or mLaA_{ΔNF}) mutant (Fig. 5, B and C) (24), suggesting that these mutations may have similar effects on MlaA structure and/or function. Interestingly, the positions of these mutations on the OmpC–MlaA models flank a hydrophobic hairpin loop (Gly¹⁴¹–Leu¹⁵⁸) within MlaA (Fig. 6A). Therefore, we hypothesized that the loop could play a functional role in MlaA and that these mutations may affect interactions with this loop. To examine this possibility, we created three separate mutations at the hairpin structure and tested each variant for MlaA function. Two of these mutations, ¹⁴⁷YVQL → 4A (L1) and ¹⁵²FYGSF → 5A (L2),




Figure 5. A triple charge-inversion mutation in the hydrophilic channel within MlaA results in gain-of-function phenotypes. *A*, a representative structure of MlaA from all-atomistic MD simulations (as in Fig. 3, top view) with position of the channel depicted by an asterisk. Negatively charged residues mutated to arginine are highlighted (magenta, in sticks). The figure was generated using the program VMD (55). *B*, analysis of SDS/EDTA sensitivity of WT and $\Delta mlaA$ strains producing indicated MlaA variants at low levels from the pET23/42 vector (*p*) (12). Serial dilutions of respective cultures were spotted on LB agar plates containing ampicillin (*Amp*), supplemented with or without 0.50% SDS and 0.5/0.8 mM EDTA, as indicated, and incubated overnight at 37 °C. *C*, representative thin-layer chromatography (TLC)/autoradiographic analysis of ^{32}P -labeled lipid A extracted from exponential phase cultures of strains described in *B*. As a positive control for lipid A palmitoylation, WT cells were treated with 25 mM EDTA for 10 min prior to extraction. Equal amounts of radioactive material were spotted for each sample. Average percentages of palmitoylation of lipid A, and the standard deviations were quantified from triplicate experiments and plotted below. For Student's *t* tests: *, $p < 0.005$ compared with WT with empty vector; **, $p < 0.001$ compared with WT p-*mlaA*-His.

are designed to disrupt interactions with other regions of MlaA. The other mutation, P151A, removes a proline that may be critical for the hairpin turn structure. The N terminus of the loop is connected to the rest of MlaA via an unstructured glycine-rich linker, which we reasoned may influence conformation of the entire hairpin structure. Thus, we constructed two additional mutants, $^{141}GVGYG \rightarrow ^{141}AVAYA$ (*3G3A*) and $^{141}GVGYG \rightarrow ^{141}PVPYP$ (*3G3P*), to reduce possible flexibility in this region. Remarkably, *L1*, *L2*, and *3G3P* mutations


resulted in similar extents of SDS/EDTA sensitivity (Fig. 6B), as well as OM outer leaflet PL accumulation (Fig. 6C), when compared with the $\Delta mlaA$ mutation. Given that these mutations also do not affect MlaA levels or interaction with OmpC (Fig. S13), we conclude that they are loss-of-function mutations. The hairpin loop, along with its surrounding structures, forms an important functional region on MlaA.

Phenotypes observed for the loop rigidifying mutation (*3G3P*) and dominant-negative mutations (*3D3R* and *mlaA**)

MlaA forms an outer membrane channel

suggest that flexibility in the hairpin loop is critical for MlaA function. We hypothesize that the hairpin loop may exist in two distinct conformations. The 3D3R or *mlaA** mutations could

alter interactions with the loop, resulting in it adopting one conformation and somehow giving rise to exacerbated and thus dominant-negative phenotypes; in the case of *mlaA**, it was



proposed that this mutation caused MlaA to be in a “leaky” or “open” state and allowed PLs to flip out to the outer leaflet of the OM (24). In contrast, the 3G3P mutation may lock the hairpin loop in a second conformation, where MlaA is in a “closed” state, thus abolishing function in PL transport. If these were true, we predict that rigidification of the hairpin loop with the 3G3P mutation would be able to correct dominant-negative phenotypes observed in the 3D3R and/or *mlaA** mutants. Indeed, the 3G3P/3D3R and 3G3P/*mlaA** combination mutants no longer exhibit dominant-negative phenotypes but behave like the 3G3P or null mutants (Fig. 6D). Again, these variants are expressed at comparable levels to the single mutants and still interact with OmpC (Fig. S13). Taken together, these results indicate clear importance of dynamics in the hairpin loop in controlling the function of MlaA.

A specific residue in the dimeric interface of OmpC is important for its function in maintaining lipid asymmetry

Given that MlaA sits in the membrane and provides a channel that putatively allows movement of PLs across the OM, it is not clear why it should bind at one of the dimeric interfaces of OmpC trimers and what the exact role of OmpC may be. To understand the importance of OmpC–MlaA interaction, we attempted to engineer monomeric OmpC constructs that we predict would no longer interact with MlaA. We installed specific mutations (G19W and/or R92L) in OmpC that were found previously to disrupt the oligomerization state of its homolog OmpF (G19W and R100L correspondingly) *in vitro* (25) (Fig. 7A). Both the OmpC_{G19W} and OmpC_{R92L} single mutants can interact with MlaA and still form trimers *in vitro*, albeit slightly destabilized compared with WT OmpC (Fig. S14). Combination of these mutations further weakens the OmpC trimer, with noticeable monomer population at physiological temperature. Intriguingly, both the double mutant and the R92L single mutant accumulated PLs in the outer leaflet of the OM (Fig. 7B), indicating that Arg⁹² is important for the role of OmpC in OM lipid asymmetry. Consistent with this idea, we demonstrated that cells expressing the OmpC_{R92A} variant also exhibit perturbations in OM lipid asymmetry. We further showed that all these *ompC* alleles can rescue severe SDS/EDTA sensitivity known for cells lacking OmpC (Fig. 7C), suggesting normal porin function; however, cells expressing OmpC_{G19W/R92L} and OmpC_{R92A}, unlike WT and OmpC_{R92L}, are still sensitive to SDS at higher concentrations of EDTA. These phenotypes mirror those observed for cells lacking MlaA, suggesting the loss of Mla function in these mutant strains. It appears that the Arg⁹² residue is critical for this function, although it is not clear why the single R92L mutation did not result in SDS/EDTA sensitivity. The exact role of Arg⁹² is not known, but the phenotypes observed for the single R92A mutation cannot be due to disrup-

tion of OmpC trimerization (Fig. S14). We conclude that OmpC has a functional role in maintaining OM lipid symmetry together with MlaA.

Discussion

Osmoporin OmpC interacts with MlaA to maintain lipid asymmetry in the OM; how this complex is organized to extract PLs from the outer leaflet of the OM is not known. In this study, we have employed photoactivatable cross-linking and MD simulations to gain insights into the molecular architecture of the OmpC–MlaA complex. We have established that MlaA interacts extensively with OmpC at one of the dimeric interfaces of the porin trimer and resides entirely within the OM lipid bilayer. We have also demonstrated that MlaA forms a hydrophilic channel, likely allowing PLs to translocate across the OM. This overall organization of the OmpC–MlaA complex is quite remarkable, especially how MlaA spans the OM and possibly gains access to outer leaflet PLs. Very few lipoproteins are known to span the OM; some notable examples include the LptDE and Wza translocons, which transport LPS and capsular polysaccharides, respectively. In the LptDE complex, the OM lipoprotein LptE serves as a plug and stretches across the bilayer through the lumen of the LptD β -barrel (26, 27). In the octameric Wza translocon, each protomer provides a C-terminal α -helix to form a pore that spans the membrane (28). MlaA is unique in that it is essentially an integral membrane protein, capable of forming a channel on its own. In many ways, MlaA behaves like typical OM β -barrel proteins, even though it is predominantly α -helical. Being overall a hydrophobic protein also poses a problem for MlaA to transit across the periplasmic space. How MlaA is shielded from the aqueous environment, in addition to the requirement of the Lol system (29), necessitates further investigation.

The recently solved crystal structures of MlaA in complex with trimeric porins revealed findings that converged with the main conclusions derived from our biochemical and modeling studies. It is quite remarkable that our studies effectively validate each other. We have noted, however, a couple of inconsistencies between the solved structures and our biochemical data, specifically *in vivo* cross-linking and SCAM (Fig. S11B). These discrepancies suggest that the crystal structure may represent only one of several possible stable conformations of MlaA, which may exist as part of the mechanism associated with lipid transport in the native OM environment. Upon close examination of these structures, we found multiple nonnative MlaA– and MlaA–porin contacts in all the crystal forms (Fig. S11C); these artificial crystal contacts, some with substantial buried surface areas, may have influenced the observed conformation of MlaA. Given that the MlaA–porin structures were

Figure 6. Flexibility in a hairpin loop structure on MlaA adjacent to the hydrophilic channel is critical for function. A, a representative structure of MlaA from all-atomistic MD simulations (as in Fig. 3B) with the hairpin loop adjacent to the hydrophilic channel highlighted. In the expanded representation, the 3D3R and *mlaA** mutations, the hairpin loop, and the glycine-rich region N-terminal to the loop are colored in cyan, orange, and black, respectively. Residues on the hairpin loop chosen for mutation are represented as sticks. The figures were generated using the program VMD (55). B, analysis of SDS/EDTA sensitivity of WT and Δ *mlaA* strains producing indicated MlaA loop variants from the pET23/42 vector (*p*). C, representative TLC/autoradiographic analysis of ³²P-labeled lipid A extracted from exponential phase cultures of strains described in B. Equal amounts of radioactive material were spotted for each sample. The average percentages of palmitoylation of lipid A and the standard deviations were quantified from triplicate experiments and plotted on the right. For Student's *t* tests: *, *p* < 0.0005 compared with WT with empty vector. D, analysis of SDS/EDTA sensitivity of WT and Δ *mlaA* strains producing indicated MlaA variants from the pET23/42 vector (*p*).

MlaA forms an outer membrane channel




Figure 7. A specific mutation in the dimeric interface of the OmpC trimer results in perturbation in OM lipid asymmetry. *A*, cartoon representation of the crystal structure of OmpC trimer illustrating the positions of Gly¹⁹ and Arg⁹² region (numbering in OmpF is given in parentheses). The figure was generated using the program PyMOL (56). *B*, analysis of SDS/EDTA sensitivity of WT and $\Delta ompC$ strains producing the indicated OmpC variants from the chromosomal locus. *C*, representative TLC/autoradiographic analysis of ³²P-labeled lipid A extracted from stationary phase cultures of strains described in *B*. Equal amounts of radioactive material were spotted for each sample. Average percentages of palmitoylation of lipid A and the standard deviations were quantified from triplicate experiments and plotted on the right. For Student's *t* tests: *, *p* < 0.005 compared with $\Delta ompC::ompC$.

also not solved in the context of a native lipid bilayer, we suspect that they do not yet provide the complete picture.

Our functional data on the OmpC–MlaA complex provide a glimpse of how PLs may translocate across the OM during maintenance of lipid asymmetry. One key aspect of MlaA function resides in a hairpin loop structure juxtaposed against the hydrophilic channel. Dynamics of this loop appear to control whether MlaA exists in a “closed” or “open” state and thus access of PLs through the channel. A mutation that likely rigidifies the loop locks MlaA in the nonfunctional closed state (Fig. 6), whereas mutations that possibly affect interactions with the loop favors the open state, and gives rise to exacerbated phenotypes (Fig. 5). Therefore, the hairpin loop may directly gate the channel, providing access for outer leaflet PLs across the OM. This idea has also been suggested based on the solved MlaA structures, where a putative disulfide bond that apparently locks the loop in position renders MlaA nonfunctional (23). It is likely that the hydrophilic channel provides a route for the passage of PL head groups across the membrane; what is not clear,

however, is how the acyl chains pass through the MlaA protein. The overall path for PLs across MlaA remains to be determined.

How OmpC participates in maintaining OM lipid asymmetry as part of the complex is not clear, especially given that MlaA alone provides a channel for PL translocation. It is possible that OmpC may play a passive role and simply be important for stabilizing the structure and orientation of MlaA in the OM. We have previously shown that MlaA also interacts with OmpF, which is expressed at comparable levels to OmpC under low osmolarity conditions (12). Removing OmpC alone, whether under high or low osmolarity conditions, causes perturbations in OM lipid asymmetry; however, removing OmpF alone has minimal effects. These results argue against a mere passive role for OmpC in PL translocation. Furthermore, we have now identified a specific residue, Arg⁹², on OmpC that is required for the maintenance of OM lipid asymmetry (Fig. 7). Therefore, we believe that OmpC plays a key functional role in the process. Arg⁹² lies in the dimeric interface of the OmpC trimer, which incidentally is where MlaA binds. Even though

this residue has been shown to be important for gating the porin (30), it is not obvious how this gating function may influence the translocation of PLs by MlaA. Instead, we speculate that being close to Tyr¹⁴⁹ and Leu³⁴⁰, Arg⁹² may somehow affect interactions between OmpC and the MlaA_{F133–R205} peptide, possibly influencing MlaA conformation in the OM and, in turn, properties of the hydrophilic channel. The role that Arg⁹² plays in OmpC–MlaA function should be further characterized.

The OmpC–MlaA complex is proposed to extract PLs from the outer leaflet of the OM and hand them over to MlaC, which resides in the periplasm. Consistent with this idea, *E. coli* MlaC has been crystallized with a bound PL and shown to interact with a complex of OmpF–MlaA *in vitro* (14). However, it is not clear how transfer of PLs from OmpC–MlaA to MlaC takes place at the OM. Because PL movement from the outer to inner leaflets of the OM is entropically disfavored, it is likely that translocation of PLs by the OmpC–MlaA complex would be coupled to transfer to MlaC; *i.e.* extracted PLs do not go into the inner leaflet. This model circumvents the problem of having to work against a PL concentration gradient between the two leaflets and allows PL transfer to MlaC to occur in an energy-independent, possibly affinity-driven, fashion. If this were true, it may be possible that MlaC also influences the function of the OmpC–MlaA complex. Specifically, binding of MlaC to the complex may be required for PL extraction from the outer leaflet of the OM. MlaC could alter the structure and/or dynamics of MlaA in the OmpC–MlaA complex, ultimately leading to efficient PL translocation across the OM.

Lipid asymmetry is critical for the OM to function as an effective permeability barrier. Thus, understanding mechanistic aspects of how bacterial cells maintain OM lipid asymmetry would guide us in designing strategies to overcome the barrier. Our work on elucidating the architecture and function of the OmpC–MlaA complex has revealed critical insights into the role of a hairpin loop on MlaA in modulating activity, a feature that can be exploited in drug discovery efforts. In particular, small molecules that can potentially influence dynamics of this loop may induce functional perturbations, thereby leading to increased sensitivity to existing antibiotics.

Experimental procedures

Bacterial strains and plasmids

All strains and plasmids used are listed in Table S1 and S2, respectively.

Growth conditions

LB broth and agar were prepared as described previously (12). Unless otherwise noted, ampicillin (Sigma–Aldrich) was used at a concentration of 200 µg/ml, chloramphenicol (Alfa Aesar, Heysham, UK) at 15 µg/ml, kanamycin (Sigma–Aldrich) at 25 µg/ml, and spectinomycin (Sigma–Aldrich) at 50 µg/ml. For cross-linking experiments, *para*-benzoyl-L-phenylalanine (*p*Bpa; Alfa Aesar) was dissolved in 1 M NaOH at 0.25 M and used at 0.25 mM unless otherwise mentioned.

Plasmid construction

To construct most plasmids, the desired gene or DNA fragments were amplified by PCR from the DNA template using primers listed in Table S3. Amplified fragments were digested with relevant restriction enzymes (New England Biolabs) and ligated into the same sites of an appropriate plasmids using T4 DNA ligase (New England Biolabs). NovaBlue competent cells were transformed with the ligation products and selected on LB plates containing appropriate antibiotics. All constructs were verified by DNA sequencing (Axil Scientific, Singapore).

Construction of chromosomal *ompC* mutants using negative selection

All chromosomal *ompC* mutations were introduced via a positive-negative selection method described previously (31). To prepare electrocompetent cells, strain MC4100 harboring pKM208 (32) grown overnight at 30 °C was inoculated into 15 ml of SOB broth with 1:100 dilution. The cells were grown at the same temperature until A_{600} reached ~0.3–0.4. 1 mM of isopropyl β-D-thiogalactopyranoside was added, and the culture was grown for another 60 min at 30 °C. The cells were then subjected to heat shock at 42 °C for 15 min, followed by incubation for 15 min on ice, with intermittent agitation. Subsequently, the cells were centrifuged at 5000 × *g* for 10 min and made competent by washing twice with prechilled sterile water followed by cold 10% glycerol. Competent cells were pelleted and resuspended in cold 10% glycerol. For positive selection, 1 µg of *kan–PrhaB–tse2* cassette amplified from pSLC-246 (31) using *ompC_NS_N5* and *ompC_NS_C3* primer pairs was transformed into the competent cells using 1-mm electroporation cuvettes (Bio-Rad) in Eppendorf Eporator® with an output voltage of 1800 V. The cells were recovered in LB with 2% glucose at 37 °C for at least 4 h, plated onto LB plates supplemented with kanamycin and 2% glucose, and incubated at 37 °C for 24 h. For negative selection, 1 µg of PCR product of *ompC* WT or mutant constructs amplified using *ompC_NS_N5_C* and *ompC_NS_C3_C* primer pairs were transformed into competent cells made from positive selection using similar procedures. After transformation, the cells were plated onto minimal (M9) plates supplemented with 0.2% rhamnose and incubated for 48 h at 37 °C. Surviving colonies were PCR-screened and verified by DNA sequencing (Axil Scientific, Singapore).

In vivo photoactivatable cross-linking

We adopted previously described protocol (19) for all *in vivo* photoactivatable cross-linking experiments. Briefly, amber stop codon (TAG) was introduced at selected positions in either pDSW206*ompC* or pCDF*mlaA–His* plasmids via site-directed mutagenesis using primers listed in Table S3. For OmpC cross-linking, MC4100 with Δ *ompC::kan* background harboring p*Sup–BpaRS–6TRN* (33) and pDSW206*ompC* were used. For MlaA cross-linking, MC4100 with Δ *mlaA::kan* background harboring p*Sup–BpaRS–6TRN* (33) and pCDF*mlaA–His* were used. An overnight 5-ml culture was grown from a single colony in LB broth supplemented with appropriate antibiotics at 37 °C. Overnight cultures were diluted 1:100 into 10 ml of the same medium containing 0.25 mM *p*Bpa and grown until A_{600} reached ~1.0. The cells were normalized by optical density

MlaA forms an outer membrane channel

before pelleting and resuspended in 1 ml of ice-cold TBS (20 mM Tris, pH 8.0, 150 mM NaCl). The samples were either used directly or irradiated with UV light at 365 nm for 20 min at 4 °C or room temperature. All samples were pelleted again and finally resuspended in 200 μ l of 2 \times Laemmli buffer, boiled for 10 min, and centrifuged at 21,000 \times *g* in a microcentrifuge for 1 min at room temperature; 15 μ l of each sample subjected to SDS–PAGE and immunoblot analyses.

Overexpression and purification of OmpC–MlaA–His complexes

All proteins were overexpressed in and purified from BL21(λ DE3) derivatives. We found that BL21(λ DE3) strains from multiple labs do not actually produce OmpC (the gene is somehow missing in these strains); therefore, to obtain OmpC–MlaA complexes, we deleted *ompF* from the chromosome and introduced *ompC* on a plasmid. OmpC–MlaA–His protein complexes were overexpressed and purified from BL21(λ DE3) cells with chromosomal $\Delta ompF::kan$ background co-transformed with either pDSW206ompC_{pBpa}, pSup–BpaRS–6TRN and pCDFmLaA–His (for *in vitro* cross-linking experiments), or pACYC184ompC and pET22b(+)*dmlaA–His* (for characterization of the WT complex). An overnight 10-ml culture was grown from a single colony in LB broth supplemented with appropriate antibiotics at 37 °C. The cell culture was then used to inoculate a 1-liter culture and grown at the same temperature until A_{600} reached \sim 0.6. For induction, 0.5 mM isopropyl β -D-thiogalactopyranoside (Axil Scientific, Singapore) was added, and the culture was grown for another 3 h at 37 °C. The cells were pelleted by centrifugation at 4,700 \times *g* for 20 min and then resuspended in 10-ml TBS containing 1 mM PMSF (Calbiochem) and 30 mM imidazole (Sigma–Aldrich). The cells were lysed with three rounds of sonication on ice (38% power, 1-s pulse on, 1-s pulse off for 3 min). The cell lysates were incubated overnight with 1% *n*-dodecyl β -D-maltoside (DDM; Calbiochem) at 4 °C. Cell debris was removed by centrifugation at 24,000 \times *g* for 30 min at 4 °C. Subsequently, supernatant was incubated with 1 ml of nickel–nitrilotriacetic acid nickel resin (Qiagen), pre-equilibrated with 20 ml of wash buffer (TBS containing 0.025% DDM and 80 mM imidazole) in a column for 1 h at 4 °C with rocking. The mixture was allowed to drain by gravity before washing vigorously with 10 \times 10 ml of wash buffer and eluted with 10 ml of elution buffer (TBS containing 0.025% DDM and 500 mM imidazole). The eluate was concentrated in an Amicon Ultra 100-kDa cutoff ultrafiltration device (Merck Millipore) by centrifugation at 4,000 \times *g* to \sim 500 μ l. The proteins were further purified by SEC system (AKTA Pure; GE Healthcare) at 4 °C on a prepacked Superdex 200 increase 10/300 GL column, using TBS containing 0.025% DDM as the eluent. Protein samples were used either directly or irradiated with UV at 365 nm for *in vivo* photoactivable cross-linking experiments.

SEC–MALS analysis to determine absolute molar masses of OmpC–MlaA–His complex

Prior to each SEC–MALS analysis, a preparative SEC was performed for BSA (Sigma–Aldrich) to separate monodisperse monomeric peak and to use as a quality control for the MALS

detectors. In each experiment, monomeric BSA was injected before the protein of interest, and the settings (calibration constant for TREOS detector; Wyatt Technology) that gave the well-characterized molar mass of BSA (66.4 kDa) were used for the molar mass calculation of the protein of interest. SEC purified OmpC–MlaA–His was concentrated to 5 mg/ml and injected into Superdex 200 Increase 10/300 GL column pre-equilibrated with TBS and 0.025% DDM. Light scattering and refractive index (*n*) data were collected online using miniDAWN TREOS (Wyatt Technology) and Optilab T-rEX (Wyatt Technology), respectively, and analyzed by ASTRA 6.1.5.22 software (Wyatt Technology). Protein-conjugate analysis available in ASTRA software was applied to calculate non-proteinaceous part of the complex. In this analysis, the refractive index increment dn/dc values (where *c* is sample concentration) of 0.143 ml/g and 0.185 ml/g were used for DDM and protein complex, respectively (34). For BSA, UV extinction coefficient of 0.66 ml/(mg \cdot cm) was used. For the OmpC–MlaA–His complex, the UV extinction coefficient was calculated to be 1.66 ml/(mg \cdot cm), based on its predicted stoichiometric ratio OmpC₃MlaA.

Affinity-purification experiments

Affinity-purification experiments were conducted using $\Delta mlaA$ strains expressing MlaA–His at low levels from the pET23/42 vector. For each strain, a 1.5-liter culture (inoculated from an overnight culture at 1:100 dilution) was grown in LB broth at 37 °C until A_{600} of \sim 0.6. The cells were pelleted by centrifugation at 4700 \times *g* for 20 min and then resuspended in 10-ml TBS containing 1 mM PMSF (Calbiochem) and 50 mM imidazole (Sigma–Aldrich). The cells were lysed with three rounds of sonication on ice (38% power, 1-s pulse on, 1-s pulse off for 3 min). Cell lysates were incubated overnight with 1% DDM (Calbiochem) at 4 °C. Cell debris was removed by centrifugation at 24,000 \times *g* for 30 min at 4 °C. Subsequently, supernatant was incubated with 1 ml of nickel–nitrilotriacetic acid resin (Qiagen), pre-equilibrated with 20 ml of wash buffer (TBS containing 0.025% DDM and 80 mM imidazole) in a column for 1 h at 4 °C with rocking. The mixture was allowed to drain by gravity before washing vigorously with 10 \times 10 ml of wash buffer and eluted with 5 ml of elution buffer (TBS containing 0.025% DDM and 500 mM imidazole). The eluate was concentrated in an Amicon Ultra 100-kDa cutoff ultrafiltration device (Merck Millipore) by centrifugation at 4,000 \times *g* to \sim 100 μ l. The concentrated sample was mixed with equal amounts of 2 \times Laemmli buffer, boiled at 100 °C for 10 min, and subjected to SDS–PAGE and immunoblot analyses.

Trypsin digestion for protein N-terminal sequencing and MS analyses

A 1 mg/ml solution of purified OmpC–MlaA–His (OmpC was either WT or substituted with *pBpa* at selected positions) complex was incubated with or without 50 μ g/ml trypsin (Sigma–Aldrich) for 1 h at room temperature. *pBpa*-substituted samples were irradiated with UV at 365 nm before trypsin digestion. The samples were then analyzed by SDS–PAGE, followed by SEC. Peak fractions from SEC for each sample were pooled, concentrated using an Amicon Ultra 100-kDa cutoff

ultrafiltration device (Merck Millipore), and resuspended in $2\times$ Laemmli sample buffer before analyses by SDS–PAGE and immunoblot using α -MlaA antibody. For N-terminal sequencing, the samples were transferred onto polyvinylidene fluoride membrane, followed by Coomassie Blue staining (1–2 s). The desired protein bands were carefully excised with a surgical scalpel. For tandem MS, protein bands were excised from a Coomassie Blue–stained Tricine gel. Samples prepared for N-terminal sequencing and tandem MS were kept in sterile 1.5-ml centrifuge tubes before submission for analyses at Tufts University Core Facility (Boston, MA) and Taplin Biological Mass Spectrometry Facility, Harvard Medical School (Boston, MA), respectively.

Substituted cysteine accessibility method

1 ml of cells was grown to exponential phase ($A_{600} = \sim 0.6$), washed twice with TBS (pH 8.0), and resuspended in 480 μ l of TBS. For the blocking step, four tubes containing 120 μ l of cell suspension were either untreated (positive and negative control tubes added with deionized H₂O) or treated with 5 mM thiol-reactive reagent *N*-ethylmaleimide (NEM; Thermo Scientific) or MTSES (Biotium). Because MTSES is membrane-impermeable, it is expected to react with the free cysteine in MlaA variants only when the residue is near or at the membrane–water boundaries or in a hydrophilic channel. In contrast, NEM is expected to label all MlaA cysteine variants because it is membrane-permeable. Reaction with MTSES or NEM blocks the particular cysteine site from subsequently labeling by maleimide-PEG (Mal-PEG; 5 kDa, Sigma–Aldrich). After agitation at room temperature for 1 h, the cells were washed twice with TBS, pelleted at $16,000\times g$, and resuspended in 100 μ l of lysis buffer (10 M urea, 1% SDS, 2 mM EDTA in 1 M Tris, pH 6.8). Both NEM- and MTSES-blocked samples and the positive control sample were exposed to 1.2 mM Mal-PEG-5k. After agitation for another hour with protection from light, all samples were added with 120 μ l of $2\times$ Laemmli buffer, boiled for 10 min, and centrifuged at $21,000\times g$ in a microcentrifuge for 1 min at room temperature; 20 μ l from each sample tubes were subjected to SDS–PAGE and immunoblot analyses.

In vivo disulfide bond analysis

Strain NR1216 ($\Delta dsbA$) harboring pET23/42*mLaA*–His expressing MlaA–His with site-specific cysteine substitutions was grown overnight in LB broth at 37 °C. 0.5 ml of overnight culture was normalized by optical density, added with trichloroacetic acid at a final concentration of $\sim 14\%$, and mixed thoroughly at 4 °C. This step was performed to prevent scrambling of disulfide bond formed in the cysteines substituted MlaA–His. Proteins precipitated for at least 30 min on ice were centrifuged at $16,000\times g$ for 10 min at 4 °C. The pellet was washed with 1 ml of ice-cold acetone and centrifuged again at $16,000\times g$ for 10 min at 4 °C. Supernatants were then aspirated, and the pellet was air dried at room temperature for at least 20 min. The samples were resuspended thoroughly with 100 μ l of either 100 mM Tris·HCl, pH 8.0, 1% SDS (for nonreduced samples), or the same buffer supplemented with 100 mM of DTT (for reduced samples) and incubated for 20 min at room temperature. The samples were finally mixed with $4\times$ Laemmli buffer, boiled for

10 min, and subjected to SDS–PAGE and immunoblotting analyses using α -His antibody.

Membrane extraction profile analysis

Adapted from a membrane extraction protocol as described (35), 500 ml of cells were grown to exponential phase ($A_{600} = \sim 0.6$). The cells were pelleted by centrifugation at $4700\times g$ for 20 min and then resuspended in 7.5 ml of TBS containing 1 mM PMSF (Calbiochem). The cells were lysed with three rounds of sonication on ice (38% power, 1-s pulse on, 1-s pulse off for 3 min). Unbroken cells were removed by centrifugation at $4,000\times g$ for 10 min. The cell lysate was collected and centrifuged at $24,000\times g$ for 1 h. The total membrane fraction (pellet) was resuspended in 4-ml TBS; 1-ml each of resuspended total membranes were pelleted at $21,100\times g$ for 1 h at 4 °C and thereafter resuspended in 1 ml of TBS, 0.1 M alkaline Na₂CO₃ (pH 11), 4 M urea, or 1% (v/v) Triton X-100, respectively. After incubation for 1 h at room temperature with occasional gentle agitation, the samples were centrifuged at $21,100\times g$ for 1 h at room temperature to collect supernatant (extracted) and pellet (membrane) fractions. The pellet fractions were each resuspended in 1 ml of TBS. All pellet and supernatant fractions were then resuspended thoroughly with 1 ml of $2\times$ Laemmli buffer, boiled for 10 min, and centrifuged at $21,100\times g$ in a microcentrifuge for 1 min at room temperature; 20 μ l from each sample tube was subjected to SDS–PAGE and immunoblot analyses.

Docking of MlaA to OmpC

The ClusPro server (22) was used to dock MlaA (ligand, UniProt ID P76506, GREMLIN model) (17) to OmpC (receptor, Protein Data Bank code 2J1N) (18). The default server settings were used in the docking procedure. The minimum distance between six residues on OmpC and the corresponding cross-linked peptide regions of MlaA was calculated for all the predicted structures obtained from the server. Two OmpC–MlaA model with the smallest average minimum distance of all residue and peptide pairs were selected as the initial structures for use in the all-atom simulations.

Simulation procedures and setup

All simulations were performed using version 5.1.4 of the GROMACS simulation package (36, 37).

All-atom simulations

In total, seven all-atom simulations were performed (Table S4). The simulations were performed using the CHARMM36 force field parameter set (38). The equations of motion were integrated using the Verlet leapfrog algorithm with a step size of 2 fs. Lengths of hydrogen bonds were constrained with the LINCS algorithm (39). Electrostatic interactions were treated using the smooth particle mesh Ewald method (40), with cutoff for short-range interactions of 1.2 nm. The van der Waals interactions were switched smoothly to zero between 1.0 and 1.2 nm. The neighbor list was updated every 20 steps. The Nose-Hoover thermostat (41, 42) with a coupling constant of 1.0 ps was used to maintain a constant system temperature of 313 K. The protein, membrane, and solvent (water and ions) were coupled to separate thermostats. The Parrinello–Rahman barostat

MlaA forms an outer membrane channel

(43) with a coupling constant of 5.0 ps was used to maintain a pressure of 1 bar. Semi-isotropic pressure coupling was used for all the membrane systems, whereas isotropic coupling was used for the solvent-only system. Initial velocities were set according to the Maxwell distribution.

Proteins were inserted into a pre-equilibrated, symmetrical 1,2-dimyristoyl-phosphatidylethanolamine membrane over 5 ns using the membed tool (44) in the GROMACS simulation package. Subsequent equilibration, with position restraints of 1000 kJ mol^{-1} placed on all nonhydrogen protein atoms, was performed for 20 ns to allow the solvent and lipids to equilibrate around the proteins. The position restraints were removed before performing the production runs.

All of the simulations performed are summarized in Table S4. For the OmpC trimer docked with MlaA in orientation 1, three separate production simulations with different initial velocities were performed for the OmpC–MlaA complex, resulting in three trajectories of 500, 320, and 130 ns in length, respectively. For the OmpC trimer docked with MlaA in orientation 2, two separate production simulations with different initial velocities were performed for the complex, resulting in two trajectories of 500 ns in length. Clustering was performed on the MlaA structures obtained from a combined trajectory of all three (MlaA orientation 1) or two (MlaA orientation 2) atomistic simulations: a total of 4750 frames spaced every 0.2 ns. The structures were assigned to clusters using RMSD with a 0.1-nm cutoff. Four and two clusters, respectively, were observed for MlaA in the two orientations to contain greater than 100 frames. The central structure of these four clusters was used to generate the representative OmpC–MlaA models (Fig. S8). *trj_cavity* was used to identify the location the pore cavity (45), and *Hole* was used to create the pore profile (46).

Temperature titration for chromosomal *ompC* mutants

Purified WT and mutant OmpC–MlaA–His complexes were aliquoted into 1.5-ml centrifuge tubes and incubated in water bath set at different temperatures for 10 min. 20 μl of each sample were transferred into separate tubes and mixed immediately with equal volume of $2\times$ Laemmli buffer and subjected to SDS–PAGE in 12% Tris–HCl gels, followed by Coomassie Blue staining (Sigma–Aldrich).

LPS labeling and lipid A isolation

Mild acid hydrolysis of ^{32}P -labeled cultures was used to isolate lipid A according to a procedure described previously (4, 12, 47) with some modifications. 5-ml cultures were grown (inoculated with overnight cultures at 1:100 dilution) in LB broth at 37 °C until A_{600} reached ~ 0.5 – 0.7 (exponential) or ~ 2 – 4 (stationary). The cultures were uniformly labeled with $1 \mu\text{Ci ml}^{-1}$ [^{32}P]disodium phosphate (PerkinElmer Life Sciences) from the start of inoculation. One MC4100 WT culture labeled with ^{32}P was treated with 25 mM EDTA, pH 8.0, for 10 min prior to harvesting. Cells (5 and 1 ml for exponential and stationary phase cultures, respectively) were harvested by centrifugation at $4700 \times g$ for 10 min and washed twice with 1 ml of PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4 , 1.8 mM KH_2PO_4 , pH 7.4) at $5000 \times g$ for 10 min. Each cell pellet was resuspended in 0.32 ml of PBS and converted into single phase

Bligh/Dyer mixture (chloroform/methanol/water 1/2/0.8) by adding 0.8 ml of methanol and 0.4 ml of chloroform. The single-phase Bligh/Dyer mixture was incubated at room temperature for 20 min, followed by centrifugation at $21,000 \times g$ for 30 min. Each pellet obtained was washed once with 1 ml of freshly made single phase Bligh/Dyer mixture and centrifuged as above. The pellet was later resuspended in 0.45 ml of 12.5 mM sodium acetate containing 1% SDS, pH 4.5. The mixture was sonicated for 15 min before incubation at 100 °C for 40 min. The mixture was converted to a two-phase Bligh/Dyer mixture (chloroform/methanol/water 2/2/1.8) by adding 0.50 ml of methanol and 0.50 ml of chloroform. The lower phase of each mixture was collected after phase partitioning by centrifugation at $21,000 \times g$ for 30 min. The collected lower phase was washed once with 1 ml of the upper phase derived from the freshly made two-phase Bligh/Dyer mixture and centrifuged as above. The final lower phase was collected after phase partitioning by centrifugation and dried under N_2 gas. The dried radiolabeled lipid A samples were redissolved in 100 μl of chloroform/methanol mixture (4/1), and 20 μl of the samples were used for scintillation counting (MicroBeta2®; PerkinElmer Life Sciences). Equal amounts of radiolabeled lipids (cpm/lane) were spotted onto the TLC plate (Silica Gel 60 F254; Merck Millipore) and were separated using the solvent system consisting of chloroform/pyridine/96% formic acid/water (50/50/14.6/4.6) (5). The TLC plate was then dried and exposed to phosphor storage screens (GE Healthcare). Phosphor screens were visualized in a phosphorimaging device (Storm 860; GE Healthcare), and the spots were analyzed by ImageQuant TL analysis software (version 7.0, GE Healthcare). The spots were quantified and averaged based on three independent experiments of lipid A isolation.

OM permeability studies

OM sensitivity against SDS/EDTA was judged by CFU analyses on LB agar plates containing indicated concentrations of SDS/EDTA. Briefly, 5-ml cultures were grown (inoculated with overnight cultures at 1:100 dilution) in LB broth at 37 °C until A_{600} reached ~ 0.4 – 0.6 . The cells were normalized by optical density, first diluted to $A_{600} = 0.1$ ($\sim 10^8$ cells) and then serially diluted (10-fold) in LB broth using 96-well microtiter plates. 2.5 μl of the diluted cultures were manually spotted onto the plates, dried, and incubated overnight at 37 °C. Plate images were visualized by *G:Box* Chemi-XT4 (Genesys version 1.4.3.0, Syngene).

SDS–PAGE, immunoblotting, and staining

All samples subjected to SDS–PAGE were mixed 1:1 with $2\times$ Laemmli buffer. Except for temperature titration experiments, the samples were subsequently either kept at room temperature or subjected to boiling at 100 °C for 10 min. Equal volumes of the samples were loaded onto the gels. As indicated in the figure legends, SDS–PAGE was performed using either 12% or 15% Tris–HCl gels (48) or 15% Tricine gel (49) at 200 V for 50 min. After SDS–PAGE, the gels were either visualized by Coomassie Blue staining or subjected to immunoblot analysis. Immunoblot analysis was performed by transferring protein bands from the gels onto polyvinylidene fluoride membranes (Immun-Blot 0.2 μm ; Bio-Rad) using semidry electroblotting system (Trans-

Blot Turbo transfer system; Bio-Rad). Membranes were blocked for 1 h at room temperature by 1× casein blocking buffer (Sigma–Aldrich), washed, and incubated with either primary antibodies (monoclonal α -MlaA (12) (1:3000) and α -OmpC (31) (1:1500), and polyclonal α -LptE (50) (1:3000), α -LptA (51) (1:6000), α -LptB (52) (1:6000), and α -BamB (53) (1:3000)) or monoclonal α -His antibody (pentahistidine) conjugated to the horseradish peroxidase (HRP) (Qiagen) at 1:5000 dilution for 1–3 h at room temperature. Secondary antibody ECLTM anti-mouse IgG–HRP and anti-rabbit IgG–HRP were used at 1:5000 dilutions. Luminata Forte Western HRP Substrate (Merck Millipore) was used to develop the membranes, and chemiluminescence signals were visualized by G:Box Chemi-XT4 (Genesys version 1.4.3.0, Syngene).

Author contributions—J. Y., K. W. T., P. J. B., and S.-S. C. conceptualization; J. Y., K. W. T., D. A. H., Z.-S. C., J. K. M., P. J. B., and S.-S. C. formal analysis; J. Y. and K. W. T. validation; J. Y., K. W. T., D. A. H., Z.-S. C., and J. K. M. investigation; J. Y., K. W. T., D. A. H., Z.-S. C., J. K. M., and S.-S. C. methodology; J. Y., K. W. T., and S.-S. C. writing-original draft; J. Y., K. W. T., D. A. H., Z.-S. C., J. K. M., P. J. B., and S.-S. C. writing-review and editing; D. A. H. software; D. A. H. and J. K. M. visualization; P. J. B. and S.-S. C. resources; P. J. B. and S.-S. C. supervision; P. J. B. and S.-S. C. funding acquisition.

Acknowledgments—We thank Swaine Chen and Varnica Khetrpal (Genome Institute of Singapore, A*STAR) for providing α -OmpC antibody and reagents for negative selection and assistance in this technique. We thank Daniel Kahne (Harvard University) and Natividad Ruiz (Ohio State University) for generous gifts of α -LptA/ α -LptE/ α -BamB and α -LptB antibodies, respectively. We also thank Michael Berne (Analytical Core Facility, Tufts Medical School) and Ross Tomaino (Taplin Mass Spectrometry Facility, Harvard Medical School) for performing Edman sequencing and MS/MS, respectively. We gratefully acknowledge computing resources provided by the National Supercomputing Center Singapore. Finally, we thank Swaine Chen for critical discussions and comments on the manuscript.

References

- Kamio, Y., and Nikaido, H. (1976) Outer membrane of *Salmonella typhimurium*: accessibility of phospholipid head groups to phospholipase c and cyanogen bromide activated dextran in the external medium. *Biochemistry* **15**, 2561–2570 [CrossRef Medline](#)
- Funahara, Y., and Nikaido, H. (1980) Asymmetric localization of lipopolysaccharides on the outer membrane of *Salmonella typhimurium*. *J. Bacteriol.* **141**, 1463–1465 [Medline](#)
- Nikaido, H. (2003) Molecular basis of bacterial outer membrane permeability revisited. *Microbiol. Mol. Biol. Rev.* **67**, 593–656 [CrossRef Medline](#)
- Jia, W., El Zoeiby, A., Petruzzello, T. N., Jayabalasingham, B., Seyedirashiti, S., and Bishop, R. E. (2004) Lipid trafficking controls endotoxin acylation in outer membranes of *Escherichia coli*. *J. Biol. Chem.* **279**, 44966–44975 [CrossRef Medline](#)
- Wu, T., McCandlish, A. C., Gronenberg, L. S., Chng, S. S., Silhavy, T. J., and Kahne, D. (2006) Identification of a protein complex that assembles lipopolysaccharide in the outer membrane of *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 11754–11759 [CrossRef Medline](#)
- Okuda, S., Sherman, D. J., Silhavy, T. J., Ruiz, N., and Kahne, D. (2016) Lipopolysaccharide transport and assembly at the outer membrane: the PEZ model. *Nat. Rev. Microbiol.* **14**, 337–345 [CrossRef Medline](#)
- Shrivastava, R., Jiang, X., and Chng, S. S. (2017) Outer membrane lipid homeostasis via retrograde phospholipid transport in *Escherichia coli*. *Mol. Microbiol.* **106**, 395–408 [CrossRef Medline](#)
- Dekker, N. (2000) Outer-membrane phospholipase A: known structure, unknown biological function. *Mol. Microbiol.* **35**, 711–717 [CrossRef Medline](#)
- Bishop, R. E. (2005) The lipid A palmitoyltransferase PagP: molecular mechanisms and role in bacterial pathogenesis. *Mol. Microbiol.* **57**, 900–912 [CrossRef Medline](#)
- Dalebroux, Z. D., Matamouros, S., Whittington, D., Bishop, R. E., and Miller, S. I. (2014) PhoPQ regulates acidic glycerophospholipid content of the *Salmonella typhimurium* outer membrane. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 1963–1968 [CrossRef Medline](#)
- Malinverni, J. C., and Silhavy, T. J. (2009) An ABC transport system that maintains lipid asymmetry in the gram-negative outer membrane. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 8009–8014 [CrossRef Medline](#)
- Chong, Z. S., Woo, W. F., and Chng, S. S. (2015) Osmoporin OmpC forms a complex with MlaA to maintain outer membrane lipid asymmetry in *Escherichia coli*. *Mol. Microbiol.* **98**, 1133–1146 [CrossRef Medline](#)
- Huang, Y. M., Miao, Y., Munguia, J., Lin, L., Nizet, V., and McCammon, J. A. (2016) Molecular dynamic study of MlaC protein in Gram-negative bacteria: conformational flexibility, solvent effect and protein-phospholipid binding. *Protein Sci.* **25**, 1430–1437 [CrossRef Medline](#)
- Ekiert, D. C., Bhabha, G., Isom, G. L., Greenan, G., Ovchinnikov, S., Henderson, I. R., Cox, J. S., and Vale, R. D. (2017) Architectures of lipid transport systems for the bacterial outer membrane. *Cell* **169**, 273–285 [CrossRef Medline](#)
- Thong, S., Ercan, B., Torta, F., Fong, Z. Y., Wong, H. Y., Wenk, M. R., and Chng, S. S. (2016) Defining key roles for auxiliary proteins in an ABC transporter that maintains bacterial outer membrane lipid asymmetry. *Life* **5**, e19042 [Medline](#)
- Pagès, J. M., James, C. E., and Winterhalter, M. (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. *Nat. Rev. Microbiol.* **6**, 893–903 [CrossRef Medline](#)
- Ovchinnikov, S., Park, H., Varghese, N., Huang, P. S., Pavlopoulos, G. A., Kim, D. E., Kamisetty, H., Kyripides, N. C., and Baker, D. (2017) Protein structure determination using metagenome sequence data. *Science* **355**, 294–298 [CrossRef Medline](#)
- Baslé, A., Rummel, G., Storici, P., Rosenbusch, J. P., and Schirmer, T. (2006) Crystal structure of osmoporin OmpC from *E. coli* at 2.0 Å. *J. Mol. Biol.* **362**, 933–942 [CrossRef Medline](#)
- Chin, J. W., Martin, A. B., King, D. S., Wang, L., and Schultz, P. G. (2002) Addition of a photocrosslinking amino acid to the genetic code of *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 11020–11024 [CrossRef Medline](#)
- Nakamura, K., and Mizushima, S. (1976) Effects of heating in dodecyl sulfate solution on the conformation and electrophoretic mobility of isolated major outer membrane proteins from *Escherichia coli* K-12. *J. Biochem.* **80**, 1411–1422 [CrossRef Medline](#)
- Tamm, L. K., Hong, H., and Liang, B. (2004) Folding and assembly of β -barrel membrane proteins. *Biochim. Biophys. Acta* **1666**, 250–263 [CrossRef Medline](#)
- Kozakov, D., Hall, D. R., Xia, B., Porter, K. A., Padhorny, D., Yueh, C., Beglov, D., and Vajda, S. (2017) The ClusPro web server for protein-protein docking. *Nat. Protoc.* **12**, 255–278 [CrossRef Medline](#)
- Abellón-Ruiz, J., Kaptan, S. S., Baslé, A., Claudi, B., Bumann, D., Kleinekathöfer, U., and van den Berg, B. (2017) Structural basis for maintenance of bacterial outer membrane lipid asymmetry. *Nat. Microbiol.* **2**, 1616–1623 [CrossRef Medline](#)
- Sutterlin, H. A., Shi, H., May, K. L., Miguel, A., Khare, S., Huang, K. C., and Silhavy, T. J. (2016) Disruption of lipid homeostasis in the Gram-negative cell envelope activates a novel cell death pathway. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E1565–E1574 [CrossRef Medline](#)
- Naveed, H., Jimenez-Morales, D., Tian, J., Pasupuleti, V., Kenney, L. J., and Liang, J. (2012) Engineered oligomerization state of OmpF protein through computational design decouples oligomer dissociation from unfolding. *J. Mol. Biol.* **419**, 89–101 [CrossRef Medline](#)

MlaA forms an outer membrane channel

26. Dong, H., Xiang, Q., Gu, Y., Wang, Z., Paterson, N. G., Stansfeld, P. J., He, C., Zhang, Y., Wang, W., and Dong, C. (2014) Structural basis for outer membrane lipopolysaccharide insertion. *Nature* **511**, 52–56 [CrossRef](#) [Medline](#)
27. Qiao, S., Luo, Q., Zhao, Y., Zhang, X. C., and Huang, Y. (2014) Structural basis for lipopolysaccharide insertion in the bacterial outer membrane. *Nature* **511**, 108–111 [CrossRef](#) [Medline](#)
28. Dong, C., Beis, K., Nesper, J., Brunkan-Lamontagne, A. L., Clarke, B. R., Whitfield, C., and Naismith, J. H. (2006) Wza the translocon for *E. coli* capsular polysaccharides defines a new class of membrane protein. *Nature* **444**, 226–229 [CrossRef](#) [Medline](#)
29. Okuda, S., and Tokuda, H. (2011) Lipoprotein sorting in bacteria. *Annu. Rev. Microbiol.* **65**, 239–259 [CrossRef](#) [Medline](#)
30. Liu, N., and Delcour, A. H. (1998) The spontaneous gating activity of OmpC porin is affected by mutations of a putative hydrogen bond network or of a salt bridge between the L3 loop and the barrel. *Protein Eng.* **11**, 797–802 [CrossRef](#) [Medline](#)
31. Khetrapal, V., Mehershahi, K., Rafee, S., Chen, S., Lim, C. L., and Chen, S. L. (2015) A set of powerful negative selection systems for unmodified Enterobacteriaceae. *Nucleic Acids Res.* **43**, e83 [CrossRef](#) [Medline](#)
32. Murphy, K. C., and Campellone, K. G. (2003) Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic *E. coli*. *BMC Mol. Biol.* **4**, 11 [CrossRef](#) [Medline](#)
33. Ryu, Y., and Schultz, P. G. (2006) Efficient incorporation of unnatural amino acids into proteins in *Escherichia coli*. *Nat. Methods* **3**, 263–265 [CrossRef](#) [Medline](#)
34. Slotboom, D. J., Duurkens, R. H., Olieman, K., and Erkens, G. B. (2008) Static light scattering to characterize membrane proteins in detergent solution. *Methods* **46**, 73–82 [CrossRef](#) [Medline](#)
35. Leo, J. C., Oberhettinger, P., and Linke, D. (2015) Assessing the outer membrane insertion and folding of multimeric transmembrane β -barrel proteins. *Methods Mol. Biol.* **1329**, 157–167 [CrossRef](#) [Medline](#)
36. Berendsen, H. J., van der Spoel, D., and van Drunen, R. (1995) GROMACS: A message-passing parallel molecular dynamics implementation. *Comput. Phys. Commun.* **91**, 43–56 [CrossRef](#)
37. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., and Berendsen, H. J. (2005) GROMACS: fast, flexible, and free. *J. Comput. Chem.* **26**, 1701–1718 [CrossRef](#) [Medline](#)
38. Best, R. B., Zhu, X., Shim, J., Lopes, P. E., Mittal, J., Feig, M., and Mackerell, A. D., Jr. (2012) Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ , ψ and side-chain χ_1 and χ_2 dihedral angles. *J. Chem. Theory Comput.* **8**, 3257–3273 [CrossRef](#) [Medline](#)
39. Hess, B., Bekker, H., Berendsen, H. J., and Fraaije, J. G. (1997) LINCS: a linear constraint solver for molecular simulations. *J. Comput. Chem.* **18**, 1463–1472 [CrossRef](#)
40. Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., and Pedersen, L. G. (1995) A smooth particle mesh Ewald method. *J. Chem. Physics* **103**, 8577–8593 [CrossRef](#)
41. Nosé, S. (1984) A molecular dynamics method for simulations in the canonical ensemble. *Mol. Physics* **52**, 255–264 [CrossRef](#)
42. Hoover, W. G. (1985) Canonical dynamics: Equilibrium phase-space distributions. *Phys. Rev. A Gen. Phys.* **31**, 1695–1697 [CrossRef](#) [Medline](#)
43. Nosé, S., and Klein, M. L. (1983) Constant pressure molecular dynamics for molecular systems. *Mol. Physics* **50**, 1055–1076 [CrossRef](#)
44. Wolf, M. G., Hoefling, M., Aponte-Santamaría, C., Grubmüller, H., and Groenhof, G. (2010) g_membed: efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation. *J. Comput. Chem.* **31**, 2169–2174 [CrossRef](#) [Medline](#)
45. Paramo, T., East, A., Garzón, D., Ulmschneider, M. B., and Bond, P. J. (2014) Efficient characterization of protein cavities within molecular simulation trajectories: trj_cavity. *J. Chem. Theory Comput.* **10**, 2151–2164 [CrossRef](#) [Medline](#)
46. Smart, O. S., Goodfellow, J. M., and Wallace, B. A. (1993) The pore dimensions of gramicidin A. *Biophys. J.* **65**, 2455–2460 [CrossRef](#) [Medline](#)
47. Zhou, Z., Lin, S., Cotter, R. J., and Raetz, C. R. (1999) Lipid A modifications characteristic of *Salmonella typhimurium* are induced by NH₄VO₃ in *Escherichia coli* K12. Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate. *J. Biol. Chem.* **274**, 18503–18514 [CrossRef](#) [Medline](#)
48. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685 [CrossRef](#) [Medline](#)
49. Schägger, H. (2006) Tricine-SDS-PAGE. *Nat. Protoc.* **1**, 16–22 [CrossRef](#) [Medline](#)
50. Chng, S. S., Ruiz, N., Chimalakonda, G., Silhavy, T. J., and Kahne, D. (2010) Characterization of the two-protein complex in *Escherichia coli* responsible for lipopolysaccharide assembly at the outer membrane. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 5363–5368 [CrossRef](#) [Medline](#)
51. Chng, S. S., Gronenberg, L. S., and Kahne, D. (2010) Proteins required for lipopolysaccharide assembly in *Escherichia coli* form a transenvelope complex. *Biochemistry* **49**, 4565–4567 [CrossRef](#) [Medline](#)
52. Sherman, D. J., Lazarus, M. B., Murphy, L., Liu, C., Walker, S., Ruiz, N., and Kahne, D. (2014) Decoupling catalytic activity from biological function of the ATPase that powers lipopolysaccharide transport. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 4982–4987 [CrossRef](#) [Medline](#)
53. Ruiz, N., Falcone, B., Kahne, D., and Silhavy, T. J. (2005) Chemical conditionality: a genetic strategy to probe organelle assembly. *Cell* **121**, 307–317 [CrossRef](#) [Medline](#)
54. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera: a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 [CrossRef](#) [Medline](#)
55. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: visual molecular dynamics. *J. Mol. Graph.* **14**, 27–38 [Medline](#)
56. DeLano, W. L. (2012) *The PyMOL Molecular Graphics System*, version 1.8, Schrödinger, LLC, New York